ZOMETA

Compare ZOMETA  to:
Compare
Compare

Generic Name for ZOMETA

Zoledronic acid 4 mg/vial; conc soln for IV infusion after dilution.

Legal Classification:

Rx

Pharmacological Class for ZOMETA

Bisphosphonate.

Manufacturer of ZOMETA

Novartis Pharmaceuticals Corp

Indications for ZOMETA

Hypercalcemia of malignancy. Adjunct in multiple myeloma and bone metastases of solid tumors.

Adult dose for ZOMETA

Give by IV infusion over at least 15 minutes. Hypercalcemia of malignancy (albumin-corrected serum calcium ≥12 mg/dL): max 4 mg; allow at least 7 days before retreating. Multiple myeloma or bone metastases: CrCl >60mL/min: 4 mg; CrCl 50–60mL/min: 3.5mg; CrCl 40–49mL/min: 3.3mg; CrCl 30–39mL/min: 3mg; CrCl <30mL/min: see literature; all: every 3–4 weeks (give oral multivitamin supplement with calcium 500 mg + Vit. D 400 IU daily).

Children's dosing for ZOMETA

Not recommended.

Contraindications for ZOMETA

Pregnancy (Cat.D).

Warnings/Precautions for ZOMETA

Not recommended for use in patients with with bone metastases and severe renal impairment. Renal or hepatic insufficiency. Check serum creatinine before each dose: withhold until serum creatinine is within 10% of baseline if serum creatinine increases by 0.5 mg/dL from a normal pre-treatment level, or by 1 mg/dL from an abnormal pre-treatment level, within 2 weeks of next dose. Assure adequate hydration when treating hypercalcemia of malignancy. Closely monitor electrolytes (esp. calcium, magnesium, phosphate), CBC/differential, hematocrit, hemoglobin. Aspirin-sensitive asthma. Avoid dental surgery (do preventative dental work before therapy). Elderly. Nursing mothers: not recommended.

Interactions for ZOMETA

Additive hypocalcemic effect with aminoglycosides, loop diuretics. Caution with other nephrotoxic drugs (eg, thalidomide).

Adverse Reactions for ZOMETA

Fever, flu-like syndrome, GI upset, anemia, dyspnea, electrolyte disturbances, musculoskeletal pain (may be severe), hypotension, CNS effects, rigors, headache, paresthesia, renal toxicity; rare: jaw osteonecrosis.

How is ZOMETA supplied?

Vials—1

Related Disease:

Bone metastases
Hypercalcemia
Multiple myeloma
Neoplasms

Related Resources

Phase 3 study of carfilzomib for the treatment of relapsed multiple myeloma

July 21, 2010

Onyx Pharmaceuticals announced that it has begun enrollment in a Phase 3 trial evaluating carfilzomib in combination with Revlimid (lenalidomide) and low dose dexamethasone in patients with relapsed multiple myeloma.

Zuplenz oral soluble film approved for nausea and vomiting

July 06, 2010

The FDA has approved Zuplenz (ondansetron oral soluble film, from Strativa) for the prevention of postoperative, highly and moderately emetogenic cancer chemotherapy-induced, and radiotherapy-induced nausea and vomiting.

Phase 3 study of ipilimumab for previously treated metastatic melanoma

June 08, 2010

Bristol-Myers Squibb announced positive results from a Phase 3 study of ipilimumab which demonstrated that overall survival (OS) was significantly extended in patients with previously-treated metastatic melanoma who received ipilimumab.

Phase 2 study of carfilzomib for the treatment of multiple myeloma

June 07, 2010

Onyx Pharmaceuticals announced interim results from an ongoing Phase 2 study of carfilzomib for the treatment of multiple myeloma.

Phase 2 trial of AMG 386 for treatment of recurrent ovarian cancer

June 07, 2010

Amgen announced that AMG 386, combined with paclitaxel, demonstrated antitumor activity in a randomized Phase 2 trial involving 161 patients with recurrent ovarian cancer.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions